Patients and Caregivers

Management of Ovarian Cancer

Take the right treatment path.

Talk to your doctor
about ROMA™.

Treatment of ovarian cancer requires a surgical procedure with 3 main goals:

  1. To appropriately stage or classify the cancer
  2. To adequately remove all cancerous tissue
  3. To proactively monitor the progression of the disease after the cancerous tissue is removed

Studies show that when these surgeries are completed by a gynecologic oncologist, patients have better outcomes compared to those treated by a gynecologist or general surgeon.9,10

Read more about the benefits of treatment by a gynecologic oncologist.

Staging cancer is important because identifying how far the disease has progressed helps to ensure the right treatment path is chosen. There are 4 main stages of ovarian cancer

Stage I—Cancer is limited to one or both ovaries.

Stage II —Cancer has extended beyond the ovaries to other areas of the pelvis (uterus, fallopian tubes, bladder, or rectum).

Stage III—Cancer has spread beyond the ovaries and pelvis to the lining of the abdomen and/or lymph nodes.

Stage IV—Cancer has spread to the liver, lungs, and/or the fluid around the lungs.

Depending on the stage and type of ovarian cancer, additional treatment in the form of chemotherapy is usually advised. Chemotherapy is a treatment that uses drugs to kill cancer cells. These drugs travel in the bloodstream and are transported to areas of the body where cancer may have spread. It is given on average for 6 months, after which time careful follow-up is necessary.

The CA 125™ test has been considered the gold standard in the management of ovarian cancer for many years, and its use helps physicians to more effectively manage patients with this disease in conjunction with standard clinical procedures. CA125 helps physicians to determine how women diagnosed with ovarian cancer are responding to chemotherapy. It is also used to identify recurrence of the disease.

Physician guidelines recommend monitoring and follow up with CA125 at each visit if a patient had elevated CA 125 levels during chemotherapy and after treatment. The CA125 value is used to indicate how the patient is responding to therapy and whether the disease is progressing.

There is a diagnostic tool that can help stratify women into likelihood groups for finding ovarian malignancy on surgery. This diagnostic tool, ROMA™ can help get the right patient to the right doctor for better patient outcomes.

The Risk of Ovarian Malignancy Algorithm (ROMA™) is a qualitative serum test that combines the results of HE4 EIA, ARCHITECT CA 125 II™ and menopausal status into a numerical score.

ROMA is intended to aid in assessing whether a premenopausal or postmenopausal woman who presents with an ovarian adnexal mass is at high or low likelihood of finding malignancy on surgery. ROMA is indicated for women who meet the following criteria: over age 18, ovarian adnexal mass present for which surgery is planned, and not yet referred to an oncologist. ROMA must be interpreted in conjunction with an independent clinical and radiological assessment. The test is not intended as a screening or stand-along diagnostic assay.

Click here for the full ROMA package insert.